Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol
Remote Digital Physiological Data Collection in Cancer: An MSK Registry Protocol
1 other identifier
observational
3,644
1 country
1
Brief Summary
The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 19, 2022
CompletedFirst Submitted
Initial submission to the registry
May 20, 2022
CompletedFirst Posted
Study publicly available on registry
May 25, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
February 9, 2026
February 1, 2026
5.1 years
May 20, 2022
February 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
establish a mechanism within the institution to prospectively collect / extract digital remote physiological data among patients with cancer
to create a repository and infrastructure to address novel questions of clinical importance.
1 year
Eligibility Criteria
Potential participants will be identified by a member of the patient's care team, a protocol investigator, or research staff at Memorial Sloan Kettering Cancer Center (MSK).
You may qualify if:
- Project 1: HealthKit
- Individuals who meet at least one of the following criteria:
- Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor
- Historical diagnosis of primary invasive solid tumor
- Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease
- Enrolled onto an investigational trial in the EDD Service
- Seen in the MSK UCC from 2021 and onwards
- Completion of Survivorship Patient Self-Assessment
- Adult without a history of cancer \<50 years of age
- Adult without a history of cancer ≥ 50 years of age
- ≥18 years old
- Own an Apple iPhone with valid iOS operating software
- Have a registered MSK MyChart account and be willing to download the MSK Remote Monitoring (RM) application onto their personal iPhone
- Self-reported "very well" comprehension of written and verbal English language
- Willing and able to provide informed consent and HIPAA authorization for the release of personal health information
- +19 more criteria
You may not qualify if:
- Project 1: HealthKit
- Unable or unwilling to successfully export and /or share physiological data
- Project 2: DigIT-Ex
- Unable or unwilling to appropriately use digital platforms or devices
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Luke Pike, MD, DPhil
Memorial Sloan Kettering Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 20, 2022
First Posted
May 25, 2022
Study Start
May 19, 2022
Primary Completion (Estimated)
July 1, 2027
Study Completion (Estimated)
July 1, 2027
Last Updated
February 9, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.